{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:47:21Z","timestamp":1790174841942,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Study Group on Diffuse Lung Disease and the Scientific Research\/Research on Intractable Diseases in the Japan Ministry of Health, Labour, and Welfare","award":["JPMH20FC1033"],"award-info":[{"award-number":["JPMH20FC1033"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>COVID-19 patients with preexisting interstitial lung disease (ILD) were reported to have a high mortality rate; however, this was based on data from the early stages of the pandemic. It is uncertain how their mortality rates have changed with the emergence of new variants of concern as well as the development of COVID-19 vaccines and treatments. It is also unclear whether having ILD still poses a risk factor for mortality. As COVID-19 continues to be a major concern, further research on COVID-19 patients with preexisting ILD is necessary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We extracted data on COVID-19 patients between January 2020\u2013August 2021 from a Japanese nationwide insurance claims database and divided them into those with and without preexisting ILD. We investigated all-cause mortality of COVID-19 patients with preexisting ILD in wild-type-, alpha-, and delta-predominant waves, to determine whether preexisting ILD was associated with increased mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 937,758 adult COVID-19 patients, 7,333 (0.8%) had preexisting ILD. The proportion of all COVID-19 patients who had preexisting ILD in the wild-type-, alpha-, and delta-predominant waves was 1.2%, 0.8%, and 0.3%, respectively, and their 60-day mortality was 16.0%, 14.6%, and 7.5%, respectively. The 60-day mortality significantly decreased from the alpha-predominant to delta-predominant waves (difference \u2212\u20097.1%, 95% confidence intervals (CI)\u2009\u2212\u20099.3% to \u2212\u20094.9%). In multivariable analysis, preexisting ILD was independently associated with increased mortality in all waves with the wild-type-predominant, odds ratio (OR) 2.10, 95% CI 1.91\u20132.30, the alpha-predominant wave, OR 2.14, 95% CI 1.84\u20132.50, and the delta-predominant wave, OR 2.10, 95%CI 1.66\u20132.66.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>All-cause mortality rates for COVID-19 patients with preexisting ILD decreased from the wild-type- to the more recent delta-predominant waves. However, these patients were consistently at higher mortality risk than those without preexisting ILD. We emphasize that careful attention should be given to patients with preexisting ILD despite the change in the COVID-19 environment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-024-02723-3","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:03:23Z","timestamp":1708517003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of preexisting interstitial lung disease on mortality in COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study"],"prefix":"10.1186","volume":"25","author":[{"given":"Koichi","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-1543","authenticated-orcid":false,"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2723_CR1","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/. Accessed 25 June 2023."},{"key":"2723_CR2","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants. Accessed 25 June 2023."},{"key":"2723_CR3","doi-asserted-by":"publisher","first-page":"2155250","DOI":"10.1080\/22221751.2022.2155250","volume":"12","author":"K Miyashita","year":"2023","unstructured":"Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H, et al. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. Emerg Microbes Infect. 2023;12:2155250.","journal-title":"Emerg Microbes Infect"},{"key":"2723_CR4","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1164\/rccm.202007-2794OC","volume":"202","author":"TM Drake","year":"2020","unstructured":"Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An International Multicenter Study. Am J Respir Crit Care Med. 2020;202:1656\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"2723_CR5","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1164\/rccm.202006-2441LE","volume":"202","author":"AJ Esposito","year":"2020","unstructured":"Esposito AJ, Menon AA, Ghosh AJ, Putman RK, Fredenburgh LE, El-Chemaly SY, et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am J Respir Crit Care Med. 2020;202:1710\u20133.","journal-title":"Am J Respir Crit Care Med"},{"key":"2723_CR6","doi-asserted-by":"crossref","unstructured":"Lee H, Choi H, Yang B, Lee SK, Park TS, Park DW et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021, 58.","DOI":"10.1183\/13993003.04125-2020"},{"key":"2723_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1164\/rccm.202007-2638LE","volume":"203","author":"L Gallay","year":"2021","unstructured":"Gallay L, Uzunhan Y, Borie R, Lazor R, Rigaud P, Marchand-Adam S, et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am J Respir Crit Care Med. 2021;203:245\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2723_CR8","doi-asserted-by":"crossref","unstructured":"Beltramo G, Cottenet J, Mariet AS, Georges M, Piroth L, Tubert-Bitter P et al. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study. Eur Respir J 2021, 58.","DOI":"10.1183\/13993003.04474-2020"},{"key":"2723_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jiac.2022.04.006","volume":"28","author":"T Yamaya","year":"2022","unstructured":"Yamaya T, Hagiwara E, Baba T, Iwasawa T, Ogura T. Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs. J Infect Chemother. 2022;28:1029\u201332.","journal-title":"J Infect Chemother"},{"key":"2723_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.37737\/ace.2.1_13","volume":"2","author":"N Hirose","year":"2020","unstructured":"Hirose N, Ishimaru M, Morita K, Yasunaga H. A review of studies using the Japanese National Database of Health Insurance Claims and Specific Health checkups. Annals Clin Epidemiol. 2020;2:13\u201326.","journal-title":"Annals Clin Epidemiol"},{"key":"2723_CR11","doi-asserted-by":"crossref","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018, 27.","DOI":"10.1183\/16000617.0076-2018"},{"key":"2723_CR12","doi-asserted-by":"publisher","first-page":"104949","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104949","volume":"29","author":"R Pranata","year":"2020","unstructured":"Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020;29:104949.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2723_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","volume":"8","author":"M Chavez-MacGregor","year":"2022","unstructured":"Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without Cancer. JAMA Oncol. 2022;8:69\u201378.","journal-title":"JAMA Oncol"},{"key":"2723_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40620-021-01206-8","volume":"35","author":"SS Jdiaa","year":"2022","unstructured":"Jdiaa SS, Mansour R, El Alayli A, Gautam A, Thomas P, Mustafa RA. COVID-19 and chronic kidney disease: an updated overview of reviews. J Nephrol. 2022;35:69\u201385.","journal-title":"J Nephrol"},{"key":"2723_CR15","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.5888\/pcd19.210228","volume":"19","author":"R Nagarajan","year":"2022","unstructured":"Nagarajan R, Krishnamoorthy Y, Rajaa S, Hariharan VS. COVID-19 severity and mortality among Chronic Liver Disease patients: a systematic review and Meta-analysis. Prev Chronic Dis. 2022;19:E53.","journal-title":"Prev Chronic Dis"},{"key":"2723_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-8587(20)30272-2","volume":"8","author":"E Barron","year":"2020","unstructured":"Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813\u201322.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2723_CR17","unstructured":"Tokyo Metropolitan Government. Tokyo Metropolitan New Coronavirus Monitoring Conference and Analysis Materials. https:\/\/www.bousai.metro.tokyo.lg.jp\/taisaku\/saigai\/1013388\/index.html. Accessed 25 June 2023."},{"key":"2723_CR18","unstructured":"Digital Agency. The Vaccination Record System. Report in Japanese. https:\/\/info.vrs.digital.go.jp\/dashboard\/. Accessed 25 June 2023."},{"key":"2723_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(21)00475-8","volume":"22","author":"KA Twohig","year":"2022","unstructured":"Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22:35\u201342.","journal-title":"Lancet Infect Dis"},{"key":"2723_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704.","journal-title":"N Engl J Med"},{"key":"2723_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795\u2013807.","journal-title":"N Engl J Med"},{"key":"2723_CR22","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813\u201326.","journal-title":"N Engl J Med"},{"key":"2723_CR23","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, Arribas L\u00f3pez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 days in patients with moderate COVID-19: a Randomized Clinical Trial. JAMA. 2020;324:1048\u201357.","journal-title":"JAMA"},{"key":"2723_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/joim.13408","volume":"291","author":"VJ Kumar","year":"2022","unstructured":"Kumar VJ, Banu S, Sasikala M, Parsa KVL, Sowpati DT, Yadav R, et al. Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: a cohort study. J Intern Med. 2022;291:380\u20133.","journal-title":"J Intern Med"},{"key":"2723_CR25","doi-asserted-by":"publisher","first-page":"105026","DOI":"10.1016\/j.jcv.2021.105026","volume":"145","author":"DM Bierle","year":"2021","unstructured":"Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. J Clin Virol. 2021;145:105026.","journal-title":"J Clin Virol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02723-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:05:54Z","timestamp":1708517154000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02723-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2723"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02723-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The institutional review board of the Hamamatsu University School of Medicine waived patient approval and informed consent because of the retrospective nature of the study and approved this study (approval no. 21\u2013024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}